Cargando…
Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
Intensive chemotherapy directed against acute myeloid leukemia of childhood is followed by profound neutropenia and high risk for bacterial and fungal infections, including viridans group streptococci as a common cause for gram-positive septicemia. Few retrospective studies have shown the efficacy o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225941/ https://www.ncbi.nlm.nih.gov/pubmed/27699447 http://dx.doi.org/10.1007/s00277-016-2833-5 |
_version_ | 1782493603879190528 |
---|---|
author | Boztug, Heidrun Mühlegger, Nora Pötschger, Ulrike Attarbaschi, Andishe Peters, Christina Mann, Georg Dworzak, Michael |
author_facet | Boztug, Heidrun Mühlegger, Nora Pötschger, Ulrike Attarbaschi, Andishe Peters, Christina Mann, Georg Dworzak, Michael |
author_sort | Boztug, Heidrun |
collection | PubMed |
description | Intensive chemotherapy directed against acute myeloid leukemia of childhood is followed by profound neutropenia and high risk for bacterial and fungal infections, including viridans group streptococci as a common cause for gram-positive septicemia. Few retrospective studies have shown the efficacy of various antibiotic prophylactic regimens in children. We retrospectively studied 50 pediatric patients treated on the AML-BFM 2004 protocol between 2005 and 2015 at St. Anna Children’s Hospital and assessed the effect of antibiotic prophylaxis on the frequency of febrile neutropenia and bacterial sepsis. Fifty pediatric patients underwent 199 evaluable chemotherapy cycles. Viridans sepsis occurred after none of 98 cycles with prophylactic administration of teicoplanin/vancomycin in comparison to 12 cases of viridans sepsis among 79 cycles without systemic antibacterial prophylaxis (0 vs. 15 %, p < 0.0001). In addition, there were significantly fewer episodes of febrile neutropenia in the teicoplanin/vancomycin group (44 % vs. no prophylaxis 82 %, p < 0.0001). Severity of infection seemed to be worse when no antibiotic prophylaxis had been administered with a higher rate of intensive care unit treatment (0/98, 0 %, vs. 4/79, 5 %, p = 0.038). So far, no increase of vancomycin-resistant enterococcus isolates in surveillance cultures was noticed. Antibiotic prophylaxis with teicoplanin (or vancomycin) appears safe and feasible and resulted in eradication of viridans sepsis and decreased incidence of febrile neutropenia in pediatric AML patients. The possibility to administer teicoplanin on alternate days on an outpatient basis or at home could contribute to patient’s quality of life and decrease health care costs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-016-2833-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5225941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-52259412017-01-24 Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia Boztug, Heidrun Mühlegger, Nora Pötschger, Ulrike Attarbaschi, Andishe Peters, Christina Mann, Georg Dworzak, Michael Ann Hematol Original Article Intensive chemotherapy directed against acute myeloid leukemia of childhood is followed by profound neutropenia and high risk for bacterial and fungal infections, including viridans group streptococci as a common cause for gram-positive septicemia. Few retrospective studies have shown the efficacy of various antibiotic prophylactic regimens in children. We retrospectively studied 50 pediatric patients treated on the AML-BFM 2004 protocol between 2005 and 2015 at St. Anna Children’s Hospital and assessed the effect of antibiotic prophylaxis on the frequency of febrile neutropenia and bacterial sepsis. Fifty pediatric patients underwent 199 evaluable chemotherapy cycles. Viridans sepsis occurred after none of 98 cycles with prophylactic administration of teicoplanin/vancomycin in comparison to 12 cases of viridans sepsis among 79 cycles without systemic antibacterial prophylaxis (0 vs. 15 %, p < 0.0001). In addition, there were significantly fewer episodes of febrile neutropenia in the teicoplanin/vancomycin group (44 % vs. no prophylaxis 82 %, p < 0.0001). Severity of infection seemed to be worse when no antibiotic prophylaxis had been administered with a higher rate of intensive care unit treatment (0/98, 0 %, vs. 4/79, 5 %, p = 0.038). So far, no increase of vancomycin-resistant enterococcus isolates in surveillance cultures was noticed. Antibiotic prophylaxis with teicoplanin (or vancomycin) appears safe and feasible and resulted in eradication of viridans sepsis and decreased incidence of febrile neutropenia in pediatric AML patients. The possibility to administer teicoplanin on alternate days on an outpatient basis or at home could contribute to patient’s quality of life and decrease health care costs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-016-2833-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-10-04 2017 /pmc/articles/PMC5225941/ /pubmed/27699447 http://dx.doi.org/10.1007/s00277-016-2833-5 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Boztug, Heidrun Mühlegger, Nora Pötschger, Ulrike Attarbaschi, Andishe Peters, Christina Mann, Georg Dworzak, Michael Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia |
title | Antibiotic prophylaxis with teicoplanin on alternate days
reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with
acute myeloid leukemia |
title_full | Antibiotic prophylaxis with teicoplanin on alternate days
reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with
acute myeloid leukemia |
title_fullStr | Antibiotic prophylaxis with teicoplanin on alternate days
reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with
acute myeloid leukemia |
title_full_unstemmed | Antibiotic prophylaxis with teicoplanin on alternate days
reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with
acute myeloid leukemia |
title_short | Antibiotic prophylaxis with teicoplanin on alternate days
reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with
acute myeloid leukemia |
title_sort | antibiotic prophylaxis with teicoplanin on alternate days
reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with
acute myeloid leukemia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225941/ https://www.ncbi.nlm.nih.gov/pubmed/27699447 http://dx.doi.org/10.1007/s00277-016-2833-5 |
work_keys_str_mv | AT boztugheidrun antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia AT muhleggernora antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia AT potschgerulrike antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia AT attarbaschiandishe antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia AT peterschristina antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia AT manngeorg antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia AT dworzakmichael antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia |